# US 2014/0155606 A1 · Quinazoline based egfr inhibitors containing a zinc binding moiety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155606 A1
- Document ID: US20140155606A1
- Status: Published application
- Kind: A1
- Application number: 13/894,542
- Filed: 2013-05-15
- Published: 2014-06-05
- Earliest claimed: 2006-09-11
- Assignees: Curis, Inc.
- Applicants: Curis, Inc.
- Inventors: Changgeng Qian; Xiong Cai; Stephen Gould
- Web page: https://patentgrep.com/patent/US20140155606A1

## CPC

- C07D 239/94: Nitrogen atoms
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.

## Claims

### Claim 1

A compound represented by formula I:
or a pharmaceutically acceptable salt, wherein
X is O, S, CH2, or —CONH—;
B is a C3 to C9 alkylene;
R1 is selected from hydrogen, C1 to C4 alkoxy or substituted C1 to C4 alkoxy;
R2 is each independently selected from halogen, C1 to C4 alkyl, C2 to C4 alkenyl, and C2 to C4 alkynyl; and
n is 1, 2 or 3.